

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) Medicament to counteract the loss of cellular differentiation in tumour and non tumour pathologies characterised in that it comprises as active principle an effective amount of at least one inhibitor compound of Reverse Transcriptase (RT) said compound being able to bind the hydrophobic pocket on the RT subunit p66.
2. (original) Medicament according to claim 1 wherein the tumour pathologies are selected in the group of leukaemia and solid tumours such as epithelial tumors, mesenchymal tumors, tumors of the nervous system, iteratocarcinomas, fibro- and osteo-sarcomas, colon carcinoma, breast carcinoma, glioma and hepatoma.
3. (currently amended) The use Method to counteract the loss of cellular differentiation in tumour and non tumour pathologies comprising the step of administering to a subject in need an effective amount of at least one inhibitor compound of Reverse Transcriptase ~~for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies.~~
4. (currently amended) The ~~use~~method according to claim 3 wherein the compound reconverts the differentiated cells into phenotypically normal cells.
5. (currently amended) The ~~use~~method according to claim 3 wherein the tumour pathologies are selected ~~in from~~ the group of leukaemia and solid tumours such as epithelial tumors, mesenchymal tumors, tumors of the nervous system, teratocarcinomas, fibro- and osteo-sarcomas, colon carcinoma, breast carcinoma, glioma and hepatoma.
6. (currently amended) The ~~use~~method according to ~~claims 3-5~~claim 3 wherein the compound is selected from the 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine class of compounds.

7. (currently amended) The ~~use~~method according to ~~claims 3-5~~claim 3 wherein the compound is selected ~~in~~from the group of: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof.

8. (currently amended) The ~~use~~method according to ~~claims 3-7~~claim 3 wherein the pharmaceutical compositions further comprise carriers and/or diluents and/or solvents and/or excipients for the preparation of compositions for oral, intravenous, intramuscular or hypodermic injection administration.

9. (currently amended) The ~~use~~method according to claims 3-8 wherein the pharmaceutical compositions are in the form of pills, suspensions or solutions.

10. (currently amended) ~~The use of~~Method to treat cell proliferation in tumour and non tumour pathologies comprising the step of administering to a subject in need an effective amount of a compound of the 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines for the preparation of pharmaceutical compositions with antiproliferative activity.

11. (currently amended) ~~The use~~Method to treat cell proliferation in tumour and non tumour pathologies comprising the step of administering to a subject in need an effective amount of at least one compound selected in from the group of: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof, for the preparation of pharmaceutical compositions with antiproliferative activity.